Furthermore, targeting CSF‐1R has been proven effective on haematopoietic malignancies, such as multiple myeloma, chronic lymphocytic leukaemia (CLL) and a subset of AML.19, 20, 21, 22, 23. The gene discussed is CSF1R; the disease is B-cell chronic lymphocytic leukemia.